Cargando…

Ketoacidosis With Canagliflozin Prescribed for Phosphoinositide 3-Kinase Inhibitor–Induced Hyperglycemia: A Case Report

Context. Many phosphoinositide-3-kinase (PI3K) inhibitors are under trial for cancer treatment. We present a patient taking taselisib who developed ketoacidosis within 1 week of starting canagliflozin. Case Description. A 69-year-old female patient with no previous history of diabetes mellitus was e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bowman, Christopher, Abramson, Vandana, Wellons, Melissa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571767/ https://www.ncbi.nlm.nih.gov/pubmed/28856166 http://dx.doi.org/10.1177/2324709617725351

Ejemplares similares

Phosphoinositide 3-Kinase Inhibitor-Induced Hyperglycemia
por: Shey, Susan, et al.
Publicado: (2021)

Canagliflozin-Induced Diabetic Ketoacidosis: Case Report and Review of the Literature
por: Turner, Jessica, et al.
Publicado: (2016)

Prolonged diabetic ketoacidosis associated with canagliflozin
por: Sloan, Gordon, et al.
Publicado: (2018)

Canagliflozin-associated diabetic ketoacidosis: a case report
por: Chai, Peter R., et al.
Publicado: (2017)

MON-LB128 Phosphoinositide 3-Kinase (PI3K) Inhibitor Induced Hyperglycemia With Alpelisib
por: Barsukova, Yuliya, et al.
Publicado: (2020)

Sodium-Glucose Cotransporter-2 Inhibitors for Hyperglycemia in Phosphoinositide 3-kinase Pathway Inhibition
por: Weintraub, Michael A, et al.
Publicado: (2023)

Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report
por: Fukuda, Masafumi, et al.
Publicado: (2020)

Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin
por: Adachi, Junichiro, et al.
Publicado: (2017)

Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern
por: Gelaye, Alehegn, et al.
Publicado: (2016)

SUN-700 Fournier’s Gangrene and Diabetic Ketoacidosis Caused by Canagliflozin
por: Stamatiades, George Alexiades, et al.
Publicado: (2020)

A Case of Euglycemic Diabetic Ketoacidosis Following Canagliflozin Therapy
por: Tuna, Kubra M, et al.
Publicado: (2021)

Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK)
por: Huang, Xueqin, et al.
Publicado: (2023)

Canagliflozin-associated Diabetic Ketoacidosis with Lower-than-anticipated Glucose Levels
por: Vadi, Sonali, et al.
Publicado: (2017)

Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
por: Erondu, Ngozi, et al.
Publicado: (2015)

Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin
por: Kelmenson, Daniel A., et al.
Publicado: (2017)

MON-LB119 Euglycemic Diabetic Ketoacidosis in a Patient on Canagliflozin Presenting With Hypoglycemia
por: Inkollu, Sindhura, et al.
Publicado: (2020)

SUN-183 Prolonged Glycosuria after Canagliflozin Discontinuation in a Patient with Euglycemic Diabetic Ketoacidosis
por: Dai, Yufei, et al.
Publicado: (2019)

Sodium-glucose Cotransporter-2 Induced Diabetic Ketoacidosis with Minimal Hyperglycemia
por: Gammons, D. Taylor, et al.
Publicado: (2018)

Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases
por: Apsel, Beth, et al.
Publicado: (2008)

Stress Induced Hyperglycemia in a Term Baby Mimicking Diabetic Ketoacidosis with Stroke
por: Mittal, Aliza, et al.
Publicado: (2013)

Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study
por: Cho, Kyu Yong, et al.
Publicado: (2021)

Inositol Polyphosphate-Based Compounds as Inhibitors of Phosphoinositide 3-Kinase-Dependent Signaling
por: Maffucci, Tania, et al.
Publicado: (2020)

Phosphoinositide 3-kinase inhibitors are effective therapeutic drugs for the treatment of hepatocellular carcinoma?
por: Park, Jeong Su, et al.
Publicado: (2020)

Management of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia
por: Goncalves, Marcus D., et al.
Publicado: (2022)

Canagliflozin Prevents Hyperglycemia-Associated Muscle Extracellular Matrix Accumulation and Improves the Adaptive Response to Aerobic Exercise
por: MacDonald, Tara L., et al.
Publicado: (2022)

Phosphoinositide-3-Kinase Is the Primary Mediator of Phosphoinositide-Dependent Inhibition in Mammalian Olfactory Receptor Neurons
por: Ukhanov, Kirill, et al.
Publicado: (2016)

The Novel Therapeutic Effect of Phosphoinositide 3-Kinase-γ Inhibitor AS605240 in Autoimmune Diabetes
por: Azzi, Jamil, et al.
Publicado: (2012)

Initiation of human astrovirus type 1 infection was blocked by inhibitors of phosphoinositide 3-kinase
por: Tange, Shoichiro, et al.
Publicado: (2013)

Effects of a Phosphoinositide-3-Kinase Inhibitor on Anaplastic Thyroid Cancer Stem Cells
por: Bozorg-Ghalati, Farzaneh, et al.
Publicado: (2017)

Identification of Novel Piperazinylquinoxaline Derivatives as Potent Phosphoinositide 3-Kinase (PI3K) Inhibitors
por: Wu, Peng, et al.
Publicado: (2012)

Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements
por: Bertucci, Alexandre, et al.
Publicado: (2023)

SUN-167 Quetiapine-Induced Hypertriglyceridemia and Hyperglycemia Presenting as Simultaneous Diabetic Ketoacidosis and Acute Pancreatitis
por: Gandhi, Shriya, et al.
Publicado: (2019)

The Role of Phosphoinositide 3-Kinase Signaling in Intestinal Inflammation
por: Cahill, Catherine M., et al.
Publicado: (2012)

The role of phosphoinositide 3-kinase subunits in chronic thyroiditis
por: Wojciechowska-Durczynska, Katarzyna, et al.
Publicado: (2012)

Phosphoinositide 3-kinase: friend and foe in cardiovascular disease
por: Ghigo, Alessandra, et al.
Publicado: (2015)

The phosphoinositide 3-kinase pathway and therapy resistance in cancer
por: Brown, Kristin K., et al.
Publicado: (2015)

Multiple Functions of Phosphoinositide-3 Kinase Enhancer (PIKE)
por: Chan, Chi Bun, et al.
Publicado: (2010)

Class (I) Phosphoinositide 3-Kinases in the Tumor Microenvironment
por: Gyori, David, et al.
Publicado: (2017)

Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition
por: Dewan, Anna K., et al.
Publicado: (2019)

Phosphoinositide 3′-Kinase γ Facilitates Polyomavirus Infection
por: Clark, Paul, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4051ce77smp7i2nob2vsciboig